BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12637944)

  • 1. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.
    Wen SF; Mahavni V; Quijano E; Shinoda J; Grace M; Musco-Hobkinson ML; Yang TY; Chen Y; Runnenbaum I; Horowitz J; Maneval D; Hutchins B; Buller R
    Cancer Gene Ther; 2003 Mar; 10(3):224-38. PubMed ID: 12637944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
    Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
    Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.
    Kim J; Hwang ES; Kim JS; You EH; Lee SH; Lee JH
    Cancer Gene Ther; 1999; 6(2):172-8. PubMed ID: 10195884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
    Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
    Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
    Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.
    Roy I; Holle L; Song W; Holle E; Wagner T; Yu X
    Anticancer Res; 2002; 22(6A):3185-9. PubMed ID: 12530063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.
    Anderson SC; Johnson DE; Harris MP; Engler H; Hancock W; Huang WM; Wills KN; Gregory RJ; Sutjipto S; Wen SF; Lofgren S; Shepard HM; Maneval DC
    Clin Cancer Res; 1998 Jul; 4(7):1649-59. PubMed ID: 9676839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53.
    Pataer A; Fanale MA; Roth JA; Swisher SG; Hunt KK
    Cancer Gene Ther; 2006 Aug; 13(8):806-14. PubMed ID: 16628227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
    Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
    Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
    Zhang S; Li Y; Li L; Zhang Y; Gao N; Zhang Z; Zhao H
    J Oral Maxillofac Surg; 2009 May; 67(5):1074-82. PubMed ID: 19375021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
    Wolf JK; Mills GB; Bazzet L; Bast RC; Roth JA; Gershenson DM
    Gynecol Oncol; 1999 Nov; 75(2):261-6. PubMed ID: 10525383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
    Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
    J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma.
    Pan JJ; Zhang SW; Chen CB; Xiao SW; Sun Y; Liu CQ; Su X; Li DM; Xu G; Xu B; Lu YY
    J Clin Oncol; 2009 Feb; 27(5):799-804. PubMed ID: 19103729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression.
    Kralj M; Husnjak K; Körbler T; Pavelić J
    Cancer Gene Ther; 2003 Jun; 10(6):457-67. PubMed ID: 12768191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.